Study: Epo is well tolerated in neonates with HIE

11/16/2012 | Medscape (free registration)

Early trial data showed erythropoietin, given in addition to hypothermia treatment, was well tolerated and may be neuroprotective for neonates with hypoxic-ischemic encephalopathy. Researchers at the University of California, San Francisco, said they plan to do a large randomized trial of Epo that will follow infants for two years to evaluate neurologic outcomes.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC